Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have received an average rating of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $13.28.
A number of equities research analysts recently issued reports on AMAG shares. Piper Jaffray Companies lowered AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and reduced their target price for the company from $9.00 to $6.00 in a research note on Wednesday, October 30th. ValuEngine lowered AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 31st. BidaskClub lowered AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Barclays reaffirmed a “buy” rating and issued a $14.00 target price (down previously from $16.00) on shares of AMAG Pharmaceuticals in a research note on Sunday, November 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, August 8th.
A number of hedge funds have recently bought and sold shares of AMAG. Campbell & CO Investment Adviser LLC purchased a new position in shares of AMAG Pharmaceuticals during the 2nd quarter worth $324,000. Strs Ohio lifted its stake in shares of AMAG Pharmaceuticals by 31.1% during the 2nd quarter. Strs Ohio now owns 67,400 shares of the specialty pharmaceutical company’s stock worth $673,000 after purchasing an additional 16,000 shares during the period. Virginia Retirement Systems ET AL purchased a new position in shares of AMAG Pharmaceuticals during the 2nd quarter worth $803,000. Systematic Financial Management LP lifted its stake in shares of AMAG Pharmaceuticals by 6.7% during the 2nd quarter. Systematic Financial Management LP now owns 91,995 shares of the specialty pharmaceutical company’s stock worth $919,000 after purchasing an additional 5,755 shares during the period. Finally, Aperio Group LLC purchased a new position in shares of AMAG Pharmaceuticals during the 2nd quarter worth $78,000.
Shares of NASDAQ:AMAG traded up $0.32 during trading on Friday, hitting $9.38. 613,200 shares of the stock were exchanged, compared to its average volume of 909,994. The company has a fifty day moving average price of $11.43 and a two-hundred day moving average price of $10.52. The company has a market cap of $315.36 million, a PE ratio of -2.42 and a beta of 0.35. The company has a current ratio of 1.67, a quick ratio of 1.53 and a debt-to-equity ratio of 0.58. AMAG Pharmaceuticals has a 12-month low of $6.81 and a 12-month high of $19.44.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.19). AMAG Pharmaceuticals had a negative net margin of 88.54% and a negative return on equity of 34.59%. The company had revenue of $84.13 million during the quarter, compared to analysts’ expectations of $88.25 million. During the same period in the previous year, the company posted $0.89 EPS. AMAG Pharmaceuticals’s quarterly revenue was down 31.2% compared to the same quarter last year. Equities research analysts anticipate that AMAG Pharmaceuticals will post -2.64 earnings per share for the current fiscal year.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.